<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>BioMed Central</PublisherName>
    <PublisherLocation>London</PublisherLocation>
    <PublisherImprintName>BioMed Central</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="Online">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12950</JournalID>
      <JournalElectronicISSN>1476-9255</JournalElectronicISSN>
      <JournalTitle>Journal of Inflammation</JournalTitle>
      <JournalAbbreviatedTitle>J Inflamm</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCB" Type="Primary">Biomedicine</JournalSubject>
        <JournalSubject Code="SCB14000" Priority="1" Type="Secondary">Immunology</JournalSubject>
        <JournalSubject Code="SCH11009" Priority="2" Type="Secondary">Allergology</JournalSubject>
        <JournalSubject Code="SCL14120" Priority="3" Type="Secondary">Cytokines and Growth Factors</JournalSubject>
        <JournalSubject Code="SCH33170" Priority="4" Type="Secondary">Rheumatology</JournalSubject>
        <JournalSubject Code="SCB21007" Priority="5" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="SCH33061" Priority="6" Type="Secondary">Gastroenterology</JournalSubject>
        <SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="Online">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>13</VolumeIDStart>
        <VolumeIDEnd>13</VolumeIDEnd>
        <VolumeIssueCount>1</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="Online">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>12</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>The Author(s)</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s12950-016-0128-1" OutputMedium="Online">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>128</ArticleID>
            <ArticleDOI>10.1186/s12950-016-0128-1</ArticleDOI>
            <ArticleCitationID>19</ArticleCitationID>
            <ArticleSequenceNumber>19</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells</ArticleTitle>
            <ArticleCategory>Research</ArticleCategory>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>11</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>7</Day>
              </RegistrationDate>
              <Received>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>16</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>7</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleFundingInformation>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100001809">National Natural Science Foundation of China</FunderName>
                <GrantNumber GrantRecipient="Au9" Type="FundRef">81160013, 81060007 and 81560321</GrantNumber>
              </Fund>
              <Fund>
                <FunderName>Science and Technique Research Projects of Guangxi</FunderName>
                <GrantNumber GrantRecipient="Au9" Type="FundRef">1140003B-93</GrantNumber>
              </Fund>
              <Fund>
                <FunderName>Key Programs of Natural Science Foundation of Guangxi</FunderName>
                <GrantNumber GrantRecipient="Au9" Type="FundRef">2011GXNSFD018039</GrantNumber>
              </Fund>
            </ArticleFundingInformation>
            <ArticleCopyright>
              <CopyrightHolderName>The Author(s).</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
              <License SubType="CC BY + CC0" Type="OpenAccess" Version="4.0">
                <SimplePara>
                           <Emphasis Type="Bold">Open Access</Emphasis>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ExternalRef>
                    <RefSource>http://creativecommons.org/licenses/by/4.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/licenses/by/4.0/" TargetType="URL"/>
                  </ExternalRef>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ExternalRef>
                    <RefSource>http://creativecommons.org/publicdomain/zero/1.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/publicdomain/zero/1.0/" TargetType="URL"/>
                  </ExternalRef>) applies to the data made available in this article, unless otherwise stated.</SimplePara>
              </License>
            </ArticleCopyright>
            <ArticleGrants Type="OpenChoice">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="OpenAccess"/>
              <BodyHTMLGrant Grant="OpenAccess"/>
              <BibliographyGrant Grant="OpenAccess"/>
              <ESMGrant Grant="OpenAccess"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1 Aff2" EqualContribution="Yes" ID="Au1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Shulin</GivenName>
                  <FamilyName>Xiang</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>xiangshulin27@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff3" EqualContribution="Yes" ID="Au2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yi</GivenName>
                  <FamilyName>Zeng</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>zengyirr@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2" CorrespondingAffiliationID="Aff2" ID="Au3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Bin</GivenName>
                  <FamilyName>Xiong</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>icuxiong@sina.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff4" ID="Au4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yueqiu</GivenName>
                  <FamilyName>Qin</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>yyfyqyq@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1 Aff5" ID="Au5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Xia</GivenName>
                  <FamilyName>Huang</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>huangxia722@126.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1 Aff5" ID="Au6">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yujie</GivenName>
                  <FamilyName>Jiang</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>jiangyujielily@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff5" ID="Au7">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Weigui</GivenName>
                  <FamilyName>Luo</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>luoweiguiluo@163.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff6" ID="Au8">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Suren</GivenName>
                  <GivenName>R.</GivenName>
                  <FamilyName>Sooranna</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>s.sooranna@imperial.ac.uk</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff7" CorrespondingAffiliationID="Aff7" ID="Au9">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Liao</GivenName>
                  <FamilyName>Pinhu</FamilyName>
                </AuthorName>
                <Contact>
                  <Email>liaopinhu@163.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>The First Clinical Medical College of Jinan University</OrgName>
                <OrgAddress>
                  <City>Guangzhou</City>
                  <Postcode>510630</Postcode>
                  <State>Guangdong Province</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Department of Intensive Care Unit</OrgDivision>
                <OrgName>the People’s Hospital of Guangxi Zhuang Autonomous Region</OrgName>
                <OrgAddress>
                  <City>Nanning</City>
                  <Postcode>530021</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Department of Central Laboratory</OrgDivision>
                <OrgName>Youjiang Medical University for Nationalities</OrgName>
                <OrgAddress>
                  <City>Baise</City>
                  <Postcode>533000</Postcode>
                  <State>Guangxi Zhuang Autonomous Region</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgDivision>Department of Digestive Medicine</OrgDivision>
                <OrgName>Youjiang Medical University for Nationalities</OrgName>
                <OrgAddress>
                  <City>Baise</City>
                  <Postcode>533000</Postcode>
                  <State>Guangxi Zhuang Autonomous Region</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff5">
                <OrgDivision>Department of Respiratory Medicine</OrgDivision>
                <OrgName>Youjiang Medical University for Nationalities</OrgName>
                <OrgAddress>
                  <City>Baise</City>
                  <Postcode>533000</Postcode>
                  <State>Guangxi Zhuang Autonomous Region</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff6">
                <OrgDivision>Department of Surgery and Cancer</OrgDivision>
                <OrgName>Imperial College London, Chelsea and Westminster Hospital</OrgName>
                <OrgAddress>
                  <City>London</City>
                  <Postcode>SW10 9NH</Postcode>
                  <Country Code="GB">UK</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff7">
                <OrgDivision>Department of Intensive Care Medicine</OrgDivision>
                <OrgName>Youjiang Medical University for Nationalities</OrgName>
                <OrgAddress>
                  <City>Baise</City>
                  <Postcode>533000</Postcode>
                  <State>Guangxi Zhuang Autonomous Region</State>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Background</Heading>
                <Para ID="Par1">Endothelin-1 (ET-1) is involved in pulmonary vascular remodeling. The aim of this study was to investigate the biochemical interactions between PPAR-γ, TGF-β1 and ET-1 in vitro.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para ID="Par2">A549 cells were pre-treated with S2505 (10 μM), S2871 (10 μM) with/without SB203580 (10 μM) for 60 min following 2 h treatment with 10 ng/mL TGF-β1. A549 cells were also transfected with positive or negative PPAR-γ plasmids for comparison. RT-PCR, ELISA, western blotting and confocal laser scanning microscopy (CLSM) were used to measure the relevant expression of mRNA, protein, mediators of pathways and nuclear factor translocation.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para ID="Par3">SB203580 inhibited TGF-β1 induced ET-1 expression in A549 cells. S2871 decreased PPAR-γ mRNA and increase TGF-β1-induced ET-1 expression. S2871 increased phosphorylation of p38 MAPK and Smad2. Cells transfected with PPAR-γ negative plasmid increased TGF-β1 induced ET-1 expression, and increased the expression of phospho-p38 MAPK and phospho-Smad2. S2505 increased PPAR-γ mRNA expression, suppressed the increased TGF-β1-induced expression of ET-1. S2505 inhibited TGF-β1 induced phosphorylation of p38 MAPK and Smad2, also the nuclear translocation of Smad2. Cells transfected with PPAR-γ positive plasmid reduced TGF-β1-induced ET-1 expression, and inhibited the expression of phospho-p38 MAPK and phospho-Smad2.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusions</Heading>
                <Para ID="Par4">TGF-β1 induced release of endothelin-1 is PPAR-γ dependent in cultured A549 cells.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>TGF-β1</Keyword>
              <Keyword>PPAR-γ</Keyword>
              <Keyword>Endothelin-1</Keyword>
            </KeywordGroup>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1">
              <Heading>Background</Heading>
              <Para ID="Par5">Pulmonary arterial hypertension (PAH) is a life-threatening illness characterized by increased pulmonary vascular resistance (PVR) following right heart dysfunction [<CitationRef CitationID="CR1">1</CitationRef>]. Several changes in the diagnosis and management of this disease have been implemented by the National Institute of Health (NIH) registry since the 1980s [<CitationRef CitationID="CR2">2</CitationRef>], but the outcome of this fatal disease although improved still remains poor [<CitationRef CitationID="CR3">3</CitationRef>, <CitationRef CitationID="CR4">4</CitationRef>]. Recent research revealed that the median survival of PAH was between 3 and 5 years [<CitationRef CitationID="CR5">5</CitationRef>, <CitationRef CitationID="CR6">6</CitationRef>].</Para>
              <Para ID="Par6">The pathogenesis of PAH still remains elusive and there is general agreement that the endothelial dysfunction and pulmonary vascular remodeling appear to be the key prerequisite reasons for the initiation of the disease. Any stimuli leading to vascular endothelial injury, vasoconstriction, cell proliferation, proinflammatory, thrombogenic functions and vascular remodeling are likely to contribute to PAH [<CitationRef CitationID="CR7">7</CitationRef>, <CitationRef CitationID="CR8">8</CitationRef>]. The increase in PVR is progressive and finally leads to right heart failure and death. Many factors may be involved in this progressive process and an understanding of molecular mechanisms of PAH has given rise to numerous lines of research and important discoveries in the last decade. The presence of inflammatory cytokines and increased expression of growth and transcriptional factors are thought to contribute directly to further recruitment of inflammatory cells and proliferation of smooth muscle and endothelial cells resulting in increased PVR [<CitationRef CitationID="CR9">9</CitationRef>]. ET-1, prostacyclin, TGF-β family and nitric oxide (NO) are closely related to pulmonary arterial smooth muscle cell (PASMC) proliferation [<CitationRef CitationID="CR10">10</CitationRef>].</Para>
              <Para ID="Par7">ET-1 is a 21-AA peptide which regulates vasoconstriction and proliferative responses in numerous cell types and recent findings have re-established the role of ET-1 in the pulmonary vascular remodeling process. ET-1 plasma levels are prominently increased in PAH patients and correlate with PVR and PAH [<CitationRef CitationID="CR10">10</CitationRef>–<CitationRef CitationID="CR13">13</CitationRef>]. The concentration of ET-1 in pulmonary circulation correlated with the increased levels of PVR, as well as the severity of the structural abnormalities found in distal pulmonary arteries as measured by intravascular ultrasound [<CitationRef CitationID="CR14">14</CitationRef>]. Factors that can affect the expression of ET-1 will also affect pulmonary vascular remodeling. TGF-β1 is one of the multifunctional peptides that regulate proliferation, differentiation and other functions in several cell types. Increased expression of TGF-β1 has been observed in PAH vessel and contribute to PASMC growth and collagen deposition [<CitationRef CitationID="CR15">15</CitationRef>]. The effects of ET-1 leading to pulmonary vascular remodeling are enhanced by the presence of TGF-β1 in human PASMC [<CitationRef CitationID="CR16">16</CitationRef>]. The pathophysiology of pulmonary hypertension differs according to the presence or absence of lung disease. Idiopathic pulmonary fibrosis (IPF) is associated with a high incidence of pulmonary hypertension [<CitationRef CitationID="CR17">17</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>]. Epithelial to mesenchymal transformation (EMT) of alveolar epithelial cells has been recognized as a potential contributor to IPF and TGF-β1 has a close relationship with EMT in A549 cells [<CitationRef CitationID="CR19">19</CitationRef>, <CitationRef CitationID="CR20">20</CitationRef>]. Previous studies suggested that TGF-β1-induced A549 cells undergo EMT via phosphorylation of Smad2 [<CitationRef CitationID="CR21">21</CitationRef>, <CitationRef CitationID="CR22">22</CitationRef>] and peroxisome proliferator-activated receptor gamma (PPAR-γ) ligands inhibited profibrotic changes in TGF-β1-stimulated cells [<CitationRef CitationID="CR23">23</CitationRef>, <CitationRef CitationID="CR24">24</CitationRef>]. PPAR-γ is a ligand-activated nuclear receptor which regulates the transcription of genes involved in adipogenesis, insulin sensitization, inflammation, as well as vascular remodeling [<CitationRef CitationID="CR25">25</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>]. Early research suggested that PPAR-γ activators inhibited oxidized low-density lipoprotein-induced induced ET-1 production in endothelial cells [<CitationRef CitationID="CR27">27</CitationRef>]. The expression of PPAR-γ was reduced in the pulmonary tissue of rat models of this disease [<CitationRef CitationID="CR28">28</CitationRef>] and pharmacological activation of PPAR-γ could effectively attenuate the upregulation of ET-1 signaling in mice or human pulmonary artery endothelial cells [<CitationRef CitationID="CR29">29</CitationRef>].</Para>
              <Para ID="Par8">The way in which TGF-β1 and PPAR-γ regulate the expression of ET-1 and what signaling pathways participate in this process remain unclear. We hypothesize that TGF-β1 can stimulate A549 cells to produce ET-1 and that while PPAR-γ may has some effects on this progress. We measured the effects of TGF-β1 and PPAR-γ on ET-1 expression and production in A549 cells by using RT-PCR, ELISA, western blot and confocal laser scanning microscopy (CLSM).</Para>
            </Section1>
            <Section1 ID="Sec2">
              <Heading>Methods</Heading>
              <Section2 ID="Sec3">
                <Heading>Cell culture</Heading>
                <Para ID="Par9">Human type II alveolar epithelial cell line A549 was purchased from the American Type Culture Collection (VR-15™). The cells were propagated in Roswell Park Memorial Institute 1640 (RPMI 1640) media (Gibco, USA) supplemented with 10 % fetal bovine serum (FBS; Hyclone,USA), 1 % penicillin/streptomycin (Solarbio, China) and maintained at 37 °C in a humidified atmosphere of 95 % air: 5 % CO2. Cells were subcultured every 3–4 days when 70–80 % confluence was reached. For all experiments, A549 cells were seeded (5,000 cells/cm<Superscript>2</Superscript>) into six-well plates for total RNA isolation, into ninety-six-well plates for ELISA experiments, or into 60-mm dishes for protein extraction. Experiments were repeated at three independent times and performed in triplicate each time. Experiments were performed when a monolayer of A549 cells achieved 70–80 % confluence and cells were serum-deprived for 24 h before the drug treatments.</Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Cell treatment and sample collection</Heading>
                <Para ID="Par10">The drug treatments consisted of 4 parts as follow: A. A549 cells were treated with TGF-β1 (Peprotech, USA) at 10 ng/mL, BMP-2 at 100 ng/mL, BMP-4 at 100 ng/mL and BMP-7 at 100 ng/mL respectively, bovine serum albumin (BSA) was used as a control. B. A549 cells were treated with SB203580 (Cell Signaling Technology, USA) and/or TGF-β1. The cells were pretreated with 10 μM SB203580 for 60 min before 10 ng/mL TGF-β1 stimulation while 0.1 % DMSO used was as vehicle control. C. A549 cells were treated with S2871 (Selleckchem, USA, USA) and/or TGF-β1. The cells were pretreated with 10 μM S2871 for 60 min before 10 ng/mL TGF-β1 stimulation while 0.1 % DMSO was used as vehicle control. D. A549 cells were treated with S2505 (Selleckchem, USA) and/or TGF-β1. The cells were pretreated with 10 μM S2505 for 60 min before 10 ng/mL TGF-β1 stimulation while 0.1 % DMSO was used as vehicle control.</Para>
                <Para ID="Par11">The culture supernatants were harvested 12 h after drug treatment for ELISA measurements of ET-1. After incubated with agonists or antagonists for 2 h, total RNA was isolated from the cells by TRIzol Reagent (Invitrogen, USA) according to the manufacturer’s instructions. RNA integrity was checked electrophoretically and purity was quantified by using spectrophotometry. Cell lysate were collected with cell lysis buffer (P0013, Beyotime Biotechnology, China) with 1 μM phenylmethanesulfonyl fluoride (PMSF) at 0, 5, 10, 15 and 30 min after drug treatment respectively according to the experimental conditions for western blotting. Total protein concentration was measured via a spectrophotometer using the bicinchoninic acid (BCA) protein assay kit (P0010S, Beyotime Biotechnology, China) with BSA utilised as the protein standard. For immunofluorescence analysis by CLSM, the cells were fixed in 4 % paraformaldehyde for 30 min after TGF-β1 treatment for 15, 30 and 60 min respectively.</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>Real-time PCR</Heading>
                <Para ID="Par12">After incubations with agonists or antagonists for 2 h, total RNA was isolated from the cells by TRIzol Reagent and reverse transcription was performed on 1 μg RNA with oligo (dT) primers in 20 μL reactions by using the PrimeScriptTM RT reagent kit with gDNA Eraser (Perfect Real Time) (TAKARA BIO INC, RR047A, Japan) according to the manufacturer’s instructions. Gene expression of ET-1, PPAR-γ and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was evaluated using real-time PCR and SYBR Green I dye (Bio-Rad, Hercules, CA). The primers of ET-1, PPAR-γ and GAPDH were obtained from Invitrogen (Life Technologies, Shanghai). The sequence of primers for the amplification of ET-1, PPAR-γ and GAPDH were as follows: ET-1 (human) forward: 5-CCAATCTTGGAACAGTCTTTTCCT-3, reverse: 5-GGACATCATTTGGGTCAACACTCC-3; PPAR-γ (human) forward: 5-ACTCCCTCATGGCAATTGAATGTC-3, reverse: 5-ATACTCTGTGATCTCCTGCACAGCC-3; GAPDH (human) forward: 5-GAAGGTGAAGGTCGGAGT-3, reverse: 5-GAAGATGGTGATGGGATTC-3. After 15 min of initial activation at 95 °C, PCR was carried out for 40 cycles at 94 °C for 15 s and 56.5 °C (ET-1) or 58.0 °C (PPAR-γ) for 30s. GAPDH was performed simultaneously and used as the housekeeping gene. The threshold cycle (Ct) value was measured, and the comparative gene expression was calculated by 2<Superscript>−△△Ct</Superscript> method as described previously [<CitationRef CitationID="CR30">30</CitationRef>].</Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>ET-1 ELISA</Heading>
                <Para ID="Par13">Confluent cells were incubated with serum-free RM1640 for 24 h prior to drug treatment. TGF-β1, SB203580, S2871 and S2505 were added into the culture supernatant for 12 h and the supernatant was harvested and stored at − 80 °C. For the SB203580 + TGF-β1, S2871 + TGF-β1 and S2505 + TGF-β1 groups, SB203580, S2871 and S2505 were added into the supernatant respectively for 60 min then incubated with TGF-β1 for 12 h. All assays were performed in triplicates and the ET-1 protein concentration in the supernatants was measured using human endothelin-1QuantiGlo ELISA kit (R&amp;D Systems, USA) according to the manufacturer’s instructions.</Para>
              </Section2>
              <Section2 ID="Sec7">
                <Heading>Western Blotting</Heading>
                <Para ID="Par14">20 μg of total protein from each sample was separated by 10 % SDS polyacrylamide gels (SDS-PAGE). After electrophoresis, separated proteins were transferred onto the polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA) and the membranes were blocked for 2 h at room temperature with 5 % BSA in TBST. Membranes were then probed with primary antibodies (1:10,000 for β-actin and 1:1000 for other antibodies) at 4 °C overnight. The antibodies used were phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb (4511, Cell Signaling Technology), p38 MAPK (D13E1) XP® Rabbit mAb (8690, Cell Signaling Technology), phospho-Smad2 (Ser465/467) (138D4) rabbit mAb (3108, Cell Signaling Technology), Smad2 (D43B4) XP® Rabbit mAb (5339, Cell Signaling Technology), phospho-SAPK/JNK (Thr183/Tyr185) (81E11) rabbit mAb (4668, Cell Signaling Technology), phospho-NF-kB p65 (Ser536) (93H1) rabbit mAb (3033, Cell Signaling Technology), NF-kB p65 (C22B4) rabbit mAb (4764, Cell Signaling Technology) and beta-actin rabbit polyclonal antibody (#4967, Cell Signaling Technology). After washing with TBST, membranes were probed with secondary antibodies (anti-rabbit IgG, HRP-linked antibody, #7074, Cell Signaling Technology) for 2 h at room temperature. Immunoblots were visualised by enhanced chemiluminescence and the image of western blots was scanned by Quantity One software. Band densities were quantified with freeware image analysis software, NIH Image (National Institute of Health, Bethesda MD, USA). The results of phosphorylated protein were normalized against the intensity of the total protein in each sample. In some western blots beta-actin was used as a protein loading control.</Para>
              </Section2>
              <Section2 ID="Sec8">
                <Heading>Plasmid transfection</Heading>
                <Para ID="Par15">A549 cells were allowed to grow till about 80 % confluency and then transfected with PPAR-γ positive or negative plasmid. The glycerol bacterial samples containing plasmids of human PPAR gamma sequence or small interfering RNA (siRNA) were synthesized by Invitrogen (Life Technologies, Shanghai). The glycerol bacterial samples were amplified in Luria-Bertani (LB) medium with 0.5 % amikacin at 37 °C overnight and the plasmid DNA extraction was performed using endofree maxi plasmid kit (TIANGEN BIOTECH, Beijing). The plasmid DNA was quantified by using spectrophotometry. Transfection was performed using LipofectamineTM 2000 reagent (Invitrogen) following the manufacturer’s instruction. Cells were incubated at 37 °C for 24 h in a humidified incubator containing 95 % air: 5 % CO<Subscript>2</Subscript> and then treated with 10 ng/mL TGF-β1. Detailed methods are provided in the online supplementary data.</Para>
              </Section2>
              <Section2 ID="Sec9">
                <Heading>Immunofluorescence analysis by confocal laser scanning microscopy (CLSM)</Heading>
                <Para ID="Par16">A549 cells were serum-deprived for 24 h before treatment after reaching 70–80 % confluence. TGF-β1 was added into the cultures at 10 ng/mL for 15, 30 and 60 min respectively. After treatment the culture supernatant was removed and the cells were washed with PBS 3 times and then fixed in 4 % paraformaldehyde for 30 min at room temperature, permeabilized by 0.1 % Triton X-100 in PBS for 20 min, blocked with 5 % BSA for 30 min. The cells were incubated with primary antibody of phospho-Smad2 rabbit mAb (3108, Cell Signaling Technology) at 4 °C overnight. After PBS washing for 3 times, secondary antibody (Alexa Fluor 488-labeled goat anti-rabbit IgG, Beyotime Inc.) was added to the cells and incubated in the dark at room temperature for 1 h. The cells were washed with PBS for 3 times and mounted with propidium iodide (PI)-containing mounting media (ZSGB-BIO, Beijing, China) for 5 min. After washing with PBS 3 times, the cells were observed and photographed by a confocal laser scanning microscope.</Para>
              </Section2>
              <Section2 ID="Sec10">
                <Heading>Statistical analysis</Heading>
                <Para ID="Par17">Data are presented as means ± standard deviation of multiple determinations. Statistical analysis was performed using SPSS for windows (version 16.0, Chicago, USA). Differences between multiple groups were compared using One-way repeated measures ANOVA. The difference between a control and a treatment group or between two treatment groups was compared by two-sample Student’s <Emphasis Type="Italic">t</Emphasis>-test where stated in the figure legends. The difference was considered statistically significant at <Emphasis Type="Italic">P</Emphasis> &lt; 0.05.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec11">
              <Heading>Results</Heading>
              <Section2 ID="Sec12">
                <Heading>TGF-β1 can promote A549 cells synthesis and secretion of ET-1</Heading>
                <Para ID="Par18">Confluent A549 cells were incubated with 10 ng/mL TGF-β1, 100 ng/mL BMP-2, 100 ng/mL BMP-4 and 100 ng/mL BMP-7 respectively. After incubation for 2 h, the total RNA was extracted to perform real-time qPCR and after 12 h incubation the supernatants were harvested to evaluate ET-1 concentrations by ELISA. The results of real-time qPCR demonstrated that 10 ng/mL TGF-β1, 100 ng/mL BMP-2 and 100 ng/mL BMP-7 increased the relative ET-1 mRNA levels respectively in A549 cells but only the TGF-β1 treatment significantly increased the levels of ET-1 protein expression when measured by ELISA (Fig. <InternalRef RefID="Fig1">1</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig1">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Effect of TGF-β1 on ET-1 in A549 cells. Confluent A549 cells were incubated with 10 ng/mL TGF-β1, 100 ng/mL BMP-2, 100 ng/mL BMP-4 and 100 ng/mL BMP-7 respectively. The incubation times were 2 h for real-time qPCR and 12 h for ELISA. The ET-1 mRNA expression is shown in Fig. <InternalRef RefID="Fig1">1a</InternalRef>. The relative ET-1 mRNA levels (normalized to GAPDH mRNA) in TGF-β1, BMP-2 and BMP-7 group were increased than those in control group (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The results of ELISA assay in Fig. <InternalRef RefID="Fig1">1b</InternalRef> demonstrated that only the TGF-β1 treatment significantly increased the levels of ET-1 protein expression (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The results are presented as means ± SD of 3 independent experiments performed in triplicate. (C, control group; TGF, TGF-β1 group; BMP-2, BMP-2 group; BMP-4, BMP-4 group; BMP-7, BMP-7 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO1">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec13">
                <Heading>SB203580 suppressed the activation of MAPK P38 signal pathway and the expression of ET-1</Heading>
                <Para ID="Par19">Confluent A549 cells were treated with 10 ng/mL TGF-β1 or 10 μM SB203580 (a p38 MAPK inhibitor) respectively while cells were pre-treated with 10 μM SB203580 for 60 min before 10 ng/mL TGF-β1 stimulation for the TGF-β1 + SB203580 group. The samples were then analyzed by real-time qPCR, ELISA and western blotting. The results of real-time qPCR and ELISA demonstrated that TGF-β1 increased the expression of ET-1 mRNA and protein. SB203580 can effectively block the TGF-β1 mediated ET-1 mRNA and protein increase. The results of western blotting demonstrated that TGF-β1 led to increased protein phosphorylation of NF-kB p65, JNK/SAPK and p38; SB203580 can effectively inhibit the expression of phospho-p38 mediated by TGF-β1 (Fig. <InternalRef RefID="Fig2">2</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig2">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Effect of SB203580 on TGF-β1-induced up-regulation of ET-1 in A549 cells. Confluent A549 cells were treated with 10 ng/mL TGF-β1 or 10 μM SB203580 respectively while cells were pre-treated with 10 μM SB203580 for 60 min before 10 ng/mL TGF-β1 stimulation for SB203580 + TGF-β1 group. The samples were analyzed by real-time qPCR, ELISA and western blotting. The results of real-time qPCR were shown in Fig. <InternalRef RefID="Fig2">2a</InternalRef>. The relative ET-1 mRNA level (normalized to GAPDH mRNA) in TGF-β1 group was significantly increased than those in control group (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The relative ET-1 mRNA level in SB203580 + TGF-β1 group was decreased compared to TGF-β1 group (#<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The results of ELISA assay in Fig. <InternalRef RefID="Fig2">2b</InternalRef> also demonstrated the same results that TGF-β1 treatment increased the levels of ET-1 protein expression (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05) and the combination of SB203580 could suppressed this effects (#<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). All the results are presented as means ± SD of 3 independent experiments performed in triplicate. Western blotting shows that TGF-β1 made the protein phosphorylation increased of NF-kB p65, JNK/SAPK (Fig. <InternalRef RefID="Fig2">2c</InternalRef>) but the inhibitors of these pathways could not suppress the ET-1 protein expression according to the results of ELISA. TGF-β1 made the protein phosphorylation increased of p38 and SB203580 can effectively inhibit the expression of phospho-p38 (Fig. <InternalRef RefID="Fig2">2d</InternalRef>). (C, control group; TGF, TGF-β1 group; SB, SB203580 group; SB + TGF, SB203580 + TGF-β1 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO2">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec14">
                <Heading>TGF-β1 mediated Smad2 phosphorylation and nuclear transfer</Heading>
                <Para ID="Par20">Confluent A549 cells were treated with 10 ng/mL TGF-β1 and total protein was extracts at 0, 5, 10, 15 and 30 min respectively for western blot analysis. For immunofluorescence analysis by CLSM, the cells were pre-treated without or with 10 μM SB203580 and then incubated with 10 ng/mL TGF-β1 for 15, 30 and 60 min respectively and nuclear transfer was observed by CLSM. The cell nuclei stained by PI were red in color and phosphor-Smad2 appeared green. The results of western blot suggested that TGF-β1 increased the phosphorylation expression of Smad2. The pictures of CLSM demonstrated that TGF-β1 mediated Smad2 nuclear transfer and this process was suppressed by SB203580 (Fig. <InternalRef RefID="Fig3">3</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig3">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>TGF-β1 mediated Smad2 phosphorylation and nuclear transfer. Confluent A549 cells were treated with 10 ng/mL TGF-β1 and cell lysates were subjected to western blotting analysis. For immunofluorescence analysis by CLSM, the cells were pre-treated without or with 10 μM SB203580 and then incubated with 10 ng/mL TGF-β1 and fixed in 4 % paraformaldehyde, treated as described in the Materials and Methods and the cells were observed and photographed by a confocal laser scanning microscope. The red fluorescence stained for cell nucleus and green fluorescence stained for phosphor-Smad2. Western blotting showed that TGF-β1 increased the phosphorylation expression of Smad2 (<Emphasis Type="Bold">a</Emphasis>). The pictures of CLSM demonstrated that TGF-β1 mediated Smad2 nuclear transfer (<Emphasis Type="Bold">b</Emphasis>), this process was suppressed by SB203580 (<Emphasis Type="Bold">c</Emphasis>) (original magnification × 400)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO3">
                      <ImageObject Color="Color" FileRef="MediaObjects/12950_2016_128_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec15">
                <Heading>Inhibition of PPAR-γ can suppress the expression of PPAR-γ mRNA and increase the expression of ET-1 mRNA and protein mediated by TGF-β1, increase the expression of P-P38 and P-Smad2</Heading>
                <Para ID="Par21">A549 cells were treated by the PPAR-γ inhibitor (10 μM S2871) with or without 10 ng/mL TGF-β1 and the samples were analyzed by real-time qPCR, ELISA and western blotting. The results demonstrated that S2871 suppressed the expression of PPAR-γ mRNA and increased the expression of ET-1 mRNA, enhanced the expression of ET-1 mRNA and protein mediated by TGF-β1 and increased the expression of phospho-P38 and phospho-Smad2 (Fig. <InternalRef RefID="Fig4">4</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig4">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Inhibition of PPAR-γ on the expression of PPAR-γ and ET-1 mRNA. A549 cells were incubated with 10 ng/mL TGF-β1 or 10 μM S2871 respectively while cells were pre-treated with 10 μM S2871 for 60 min before 10 ng/mL TGF-β1 stimulation for S2871 + TGF-β1 group. Then the samples were collected and analyzed by real-time qPCR, ELISA and western blotting as described previously. The relative PPAR-γ mRNA level (normalized to GAPDH mRNA) in S2871 group was significantly decreased (<Emphasis Type="Bold">a</Emphasis>) while compared to control group and the ET-1 level was significantly increased (<Emphasis Type="Bold">b</Emphasis>) (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The increased expression of ET-1 mRNA (<Emphasis Type="Bold">c</Emphasis>) and protein (<Emphasis Type="Bold">d</Emphasis>) mediated by TGF-β1was enhanced by S2871 (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). Western blotting showed that S2871 increased the expression of phospho-P38 and phospho-Smad2 (<Emphasis Type="Bold">e</Emphasis>). The results are presented as means ± SD of 3 independent experiments performed in triplicate. (C, control group; S, S2871 group; TGF, TGF-β1 group; S + TGF, S2871 + TGF-β1 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO4">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec16">
                <Heading>PPAR-γ silencing enhanced the expression of ET-1 mRNA and protein mediated by TGF-β1, increase the expression of phospho-P38 and phospho-Smad2</Heading>
                <Para ID="Par22">A549 cells were allowed to grow and attain about 80 % confluency and the transfection with PPAR-γ siRNA plasmid or control vectors (negative control) was performed using LipofectamineTM 2000 reagent. Cells were incubated at 37 °C for 24 h in an incubator containing 95 % air: 5 % CO<Subscript>2</Subscript> and full humidity and then treated with 10 ng/mL TGF-β1. The samples were collected and analyzed by real-time qPCR, ELISA and western blotting as described in the materials and methods. The results of RT qPCR and ELISA showed that PPAR-γ silencing reduced the expression of PPAR-γ mRNA, slightly increased the expression of protein with no statistical significance observed, but significantly increased the expression of ET-1 mRNA expression and protein mediated by TGF-β1. PPAR-γ silencing increased the expression of phospho-P38 and phospho-Smad2 according to western blotting analysis (Fig. <InternalRef RefID="Fig5">5</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig5">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 5</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Silencing of PPAR-γ silence on the expression of ET-1. A549 cells were transfected with PPAR-γ siRNA plasmid or control vectors (<Emphasis Type="Italic">negative control</Emphasis>) using Lipofectamine<Superscript>TM</Superscript> 2000 reagent and incubated at 37 °C for 24 h in an incubator containing 95 % air: 5 % CO2 and full humidity. Then transfected cells were treated with 10 ng/mL TGF-β1and the samples were collected and analyzed by real-time qPCR, ELISA and western blotting. The results of electrophoresis and real-time qPCR showed that PPAR-γ silencing reduced the expression of PPAR-γ mRNA (<Emphasis Type="Bold">a</Emphasis>, <Emphasis Type="Bold">b</Emphasis>) (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05 while compared to NC). The results of RT qPCR (<Emphasis Type="Bold">c</Emphasis>) and ELISA (<Emphasis Type="Bold">d</Emphasis>) showed that PPAR-γ silencing slightly decreased the expression of ET-1 mRNA expression (<Emphasis Type="Italic">p</Emphasis> = 0.5206 while compared to NC) and increased the expression of ET-1 protein with no statistical significance (<Emphasis Type="Italic">p</Emphasis> = 0.0902 while compared to NC). The increased ET-1 mRNA level (<Emphasis Type="Bold">c</Emphasis>) and protein concentration (<Emphasis Type="Bold">d</Emphasis>) mediated by TGF-β1 was enhanced by transfection of PPAR-γ siRNA plasmid with statistical significance (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05 while PPARsiRNA + TGF group compared to TGF group). Western blotting showed that PPAR-γ silencing increased the expression of phospho-p38 and phospho-Smad2 (<Emphasis Type="Bold">e</Emphasis>). The results are presented as means ± SD of 3 independent experiments. (NC, negative control group; PPARsiRNA, PPAR-γ silencing group; TGF, TGF-β1 group; PPARsiRNA + TGF, PPAR-γ silencing + TGF-β1 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO5">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig5_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec17">
                <Heading>S2505 can increase the expression of PPAR-γ mRNA and suppress the expression of ET-1 mRNA and protein mediated by TGF-β1, decrease the expression of P-P38 and P-Smad2</Heading>
                <Para ID="Par23">A549 cells were incubated with PPAR-γ agonist (10 μM S2505) in the presence or absence of 10 ng/mL TGF-β1 and the samples were analyzed by real-time qPCR, ELISA and western blots. The results demonstrated that the PPAR-γ agonist, S2505, increased the expression of PPAR-γ mRNA, reduced the expression of ET-1 mRNA and suppressed the increased expression of ET-1 mRNA and protein mediated by TGF-β1. It also inhibited the expression of phospho-P38 and phospho-Smad2 (Fig. <InternalRef RefID="Fig6">6</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig6">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 6</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Effect of S2505 on the expression of PPAR-γ and ET-1 mRNA. A549 cells were incubated with 10 ng/mL TGF-β1 or 10 μM S2505 respectively while cells were pre-treated with 10 μM S2505 for 60 min before 10 ng/mL TGF-β1 stimulation for the S2505 + TGF-β1 group. Then the samples were collected and analyzed by real-time qPCR, ELISA and western blotting. The relative PPAR-γ mRNA level (normalized to GAPDH mRNA) in S2505 group was significantly increased (<Emphasis Type="Bold">a</Emphasis>) while compared to control group and the ET-1 level was significantly decreased (<Emphasis Type="Bold">b</Emphasis>) (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The increased expression of ET-1 mRNA (<Emphasis Type="Bold">c</Emphasis>) and protein (<Emphasis Type="Bold">d</Emphasis>) mediated by TGF-β1was suppressed by S2505 (#<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). Western blotting showed that S2505 decreased the expression of phospho-P38 and phospho-Smad2 (<Emphasis Type="Bold">e</Emphasis>). The results are presented as means ± SD of 3 independent experiments performed in triplicate. (C, control group; S2505, S2505 group; TGF, TGF-β1 group; S2505 + TGF, S2505 + TGF-β1 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO6">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig6_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec18">
                <Heading>PPAR-γ gene over-expression suppressed the expression of ET-1 mRNA and protein mediated by TGF-β1, increase the expression of P-P38 and P-Smad2</Heading>
                <Para ID="Par24">A549 cells were allowed to grow till about 80 % confluency and the transfection with PPAR-γ plasmid or control vectors (negative control) was performed using LipofectamineTM 2000 reagent. Cells were incubated at 37 °C for 24 h in an incubator containing 95 % air: 5 % CO<Subscript>2</Subscript> and full humidity and then treated with 10 ng/mL TGF-β1. The samples were collected and analyzed by real-time qPCR, ELISA and western blotting. The results of RT qPCR and ELISA showed that PPAR-γ gene over-expression increased the expression of PPAR-γ mRNA, reduced the expression of ET-1 mRNA as well as the increased expression of ET-1 protein mediated by TGF-β1. PPAR-γ gene over-expression inhibited the expression of phospho-P38 and phospho-Smad2 according to western blots (Fig. <InternalRef RefID="Fig7">7</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig7">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 7</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>PPAR-γ gene over-expression suppresses the expression of ET-1 mRNA and protein. A549 cells were transfected with PPAR-γ plasmid or control vectors (<Emphasis Type="Italic">negative control</Emphasis>) using LipofectamineTM 2000 reagent and incubated at 37 °C for 24 h in an incubator containing 95 % air, 5 % CO2 and full humidity. The cells were then treated with 10 ng/mL TGF-β1 and the samples were analyzed by real-time qPCR, ELISA and western blotting. The results of real-time qPCR showed that the relative PPAR-γ mRNA level (normalized to GAPDH mRNA) in PPAR-γ transfection group was significantly increased than those in control group (<Emphasis Type="Bold">a</Emphasis>) and ET-1 mRNA level was significantly decreased (<Emphasis Type="Bold">b</Emphasis>) (*<Emphasis Type="Italic">p</Emphasis> &lt; 0.05). The increased ET-1 mRNA level (<Emphasis Type="Bold">b</Emphasis>) and protein concentration (<Emphasis Type="Bold">c</Emphasis>) mediated by TGF-β1 was suppressed by transfection of PPAR-γ plasmid. Western blotting showed that PPAR-γ gene over-expression decreased the expression of phospho-P38 and phospho-Smad2 (<Emphasis Type="Bold">d</Emphasis>). The results are presented as means ± SD of 3 independent experiments. (NC, negative control group; PPARγ, PPAR-γ plasmid transfection group; TGF, TGF-β1 group; PPARγ + TGF, PPAR-γ plasmid transfection + TGF-β1 group)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO7">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12950_2016_128_Fig7_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec19">
              <Heading>Discussion</Heading>
              <Para ID="Par25">The pathogenesis of PAH still remains elusive, partly because many diseases can lead to PAH and multiple signaling pathways are implicated in this process. There is increasing evidence that the increased expression of ET-1 and the activation of MAPKs are linked to PAH [<CitationRef CitationID="CR10">10</CitationRef>, <CitationRef CitationID="CR31">31</CitationRef>]. Interaction of MAPK with TGF-β1 activated signaling cascades were associated with PAH [<CitationRef CitationID="CR15">15</CitationRef>, <CitationRef CitationID="CR32">32</CitationRef>]. The serum levels of TGF-β1 were significantly higher in patients with schistosomiasis-associated PAH compared with patients with schistosomiasis but without PAH [<CitationRef CitationID="CR33">33</CitationRef>] and TGF-β induced ET-1 expression [<CitationRef CitationID="CR34">34</CitationRef>–<CitationRef CitationID="CR36">36</CitationRef>]. PPAR-γ is a ligand-activated nuclear receptor and early research suggested that PPAR-γ activators suppressed the ET-1 production both in vitro and in vivo [<CitationRef CitationID="CR27">27</CitationRef>, <CitationRef CitationID="CR29">29</CitationRef>, <CitationRef CitationID="CR37">37</CitationRef>]. The way in which TGF-β1 and PPAR-γ regulate the expression of ET-1 and what signaling pathways participate in this process remains unclear. The aim of our study was to investigate the interactions between PPAR-γ, TGF-β1 and ET-1 and the underlying biochemical mechanisms whereby this occurs in A549 cells.</Para>
              <Para ID="Par26">We demonstrated that TGF-β1 could significantly promote the expression of ET-1 mRNA and protein in A549 cells, increase the phosphorylation status of P38 MAPK and Smad2. SB203580 pre-treated A549 cells, resulted in the inhibition of p38 MAPK transduction and nuclear transfer of Smad2 respectively and a suppressive effect on the TGF-β1-induced production of ET-1. These results suggest that both p38 MAPK and Smad2 are involved in TGF-β1 mediated release of ET-1 by A549 cells. These results are consistent with previous studies suggesting that TGF-β1 strongly stimulated the synthesis and secretion of ET-1 in endothelial cells [<CitationRef CitationID="CR36">36</CitationRef>, <CitationRef CitationID="CR38">38</CitationRef>], pancreatic stellate cells [<CitationRef CitationID="CR35">35</CitationRef>] and lung fibroblasts [<CitationRef CitationID="CR34">34</CitationRef>]. TGF-β signaling should be a complex phenomenon and several studies with cell and animal models have reported that TGF-β induced ET-1 expression is mediated through the ALK5/Smad3 and p38 MAPK pathways [<CitationRef CitationID="CR36">36</CitationRef>, <CitationRef CitationID="CR39">39</CitationRef>]. TGF-β increased Smad2 and Smad3 phosphorylation and promoted Smad hetero-complex formation and nuclear accumulation in myofibroblasts [<CitationRef CitationID="CR40">40</CitationRef>]. Our results demonstrate that TGF-β1, 100 ng/mL BMP-2 and 100 ng/mL BMP-7 increased the relative ET-1 mRNA levels respectively in A549 cells but only the TGF-β1 treatment significantly increased the levels of ET-1 protein expression. There may be several reasons as to why BMP-2 and BMP-7 could not significantly increase the expression of ET-1 protein as well as ET-1 mRNA. The process from ET-1 mRNA to protein expression included translation, post-translational processing and secretion to certain tissues, and multiple factors participate in this process. Any alterations in the various steps in this process would lead to the inconsistencies between mRNA and protein levels while the result of protein expression is probably more reliable index. We investigated the possible pathways by western blot analysis and the results showed that TGF-β1 allowed increases in protein phosphorylation of NF-kB p65, JNK/SAPK but the inhibitors of these pathways could not suppress the ET-1 protein expression when the results of ELISA were considered. It was also found that TGF-β1 allowed increases in protein phosphorylation of p38 MAPK and Smad2 and that SB203580 can effectively inhibit the expression of phspho-p38 MAPK and the nuclear transfer Smad2. Therefore our results strongly suggest that both p38 MAPK and Smad2 were involved in the release of ET-1 mediated by TGF-β1.</Para>
              <Para ID="Par27">Moreover, we have demonstrated that transfecting cells with PPAR-γ siRNA plasmid or pre-treating cells with S2871 increased the expression of phospho-p38 MAPK and phospho-Smad2 and enhanced the expression of ET-1 mRNA and protein mediated by TGF-β1. However, transfecting cells with PPAR-γ plasmid or pre-treating cells with S2505 decreased the expression of phospho-P38 MAPK and phospho-Smad2 and suppressed the expression of ET-1 mRNA and protein mediated by TGF-β1. These results suggest the TGF-induced ET-1 release was dependent on PPAR-γ. Others have shown that PPAR-γ agonist rosiglitazone attenuated ET-1-induced pulmonary vasoconstriction in Sprague-Dawley rats [<CitationRef CitationID="CR37">37</CitationRef>, <CitationRef CitationID="CR41">41</CitationRef>–<CitationRef CitationID="CR43">43</CitationRef>] and inhibited the activation of p38 MAPK in murine macrophages [<CitationRef CitationID="CR44">44</CitationRef>]. Rosiglitazone increased expression of PPAR-γ mRNA and also suppressed the expression of ET-1 mRNA in animal models [<CitationRef CitationID="CR28">28</CitationRef>, <CitationRef CitationID="CR45">45</CitationRef>]. When human pulmonary artery endothelial cells were transfected with PPAR-γ siRNA and this was shown to reduce PPAR-γ protein and increased ET-1 protein [<CitationRef CitationID="CR46">46</CitationRef>].</Para>
              <Para ID="Par28">In this study, we showed that TGF-β1 promoted the synthesis and secretion of ET-1 in A549 cells, increased the expression of phospho-p38 MAPK and phospho-Smad2 and induced an increase in nuclear transfer of Smad2. SB203580 suppressed the activation of MAPK P38 signal pathway, nuclear transfer of Smad2 and the expression of ET-1. Inhibition of PPAR-γ or PPAR-γ gene silencing suppressed the expression of PPAR-γ mRNA and increased the expression of ET-1 mRNA and protein mediated by TGF-β1 and also increased the expression of phospho-P38 MAPK and phospho-Smad2. However, activation of PPAR-γ or PPAR-γ gene over-expression suppressed the expression of ET-1 mRNA and protein mediated by TGF-β1 and increased the expression of phospho-p38 and phospho-Smad2. These results suggest that the release of TGF-induced ET-1 depended on PPAR-γ through the p38 MAPK and Smad2 pathways. PPAR-γ could, therefore, be considered as a potential therapeutic target for PAH. However, in the present study, we investigated only the interaction between PPAR-γ, TGF-β1 and ET-1 in vitro. Therefore, there is a need to further study the relationship between PPAR-γ, TGF-β1 and ET-1 in vivo and to investigate the anti- vasoconstriction effect of PPAR-γ and its potential role in PAH treatment.</Para>
            </Section1>
            <Section1 ID="Sec20">
              <Heading>Conclusions</Heading>
              <Para ID="Par29">In conclusion, this study shows that TGF-β1-induced production of ET-1, increased phosphorylation of p38 MAPK and Smad2 nuclear transfer could be prevented by using SB20308 and regulated by PPAR-γ, suggested that p38 MAPK and Smad2 signaling transduction is involved in TGF-β1 induced ET-1 release and that this process was PPAR-γ dependent in A549 cells.</Para>
            </Section1>
            <Section1 ID="Sec21">
              <Heading>Abbreviations</Heading>
              <Para ID="Par30">CLSM, confocal laser scanning microscopy; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; ET-1, endothelin-1; mAb, monoclonal antibody; PAH, pulmonary arterial hypertension; PASMC, pulmonary arterial smooth muscle cell; PPAR-γ, peroxisome proliferator-activated receptor gamma; PVR, pulmonary vascular resistance; TGF-β1, transforming growth factor beta 1</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/12950_2016_Article_128.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgements</Heading>
              <SimplePara>This study was supported by grants from the National Natural Science Foundation of China, Nos. 81160013, 81060007 and 81560321, Science and Technique Research Projects of Guangxi, No.1140003B-93 and the Key Programs of Natural Science Foundation of Guangxi, No.2011GXNSFD018039.</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Authors’ contributions</Heading>
                <Para ID="Par31">S.X., Y.Z., Y.Q, X.H., Y.J., and W.L., were involved with acquisition, analysis, or interpretation of the data. L.P., B.X. and S.R.S. contributed to the design and the conception of the study and interpretation of the data. All authors were involved with drafting/revising and approving the manuscript.</Para>
              </FormalPara>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Competing interests</Heading>
                <Para ID="Par32">The authors declare that they have no competing interests.</Para>
              </FormalPara>
            </Acknowledgments>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Farber</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Loscalzo</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>351</VolumeID>
                  <FirstPage>1655</FirstPage>
                  <LastPage>1665</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXos1Whtbg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMra035488</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15483284</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GE</Initials>
                    <FamilyName>D’Alonzo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Barst</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Ayres</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EH</Initials>
                    <FamilyName>Bergofsky</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BH</Initials>
                    <FamilyName>Brundage</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KM</Initials>
                    <FamilyName>Detre</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AP</Initials>
                    <FamilyName>Fishman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Goldring</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BM</Initials>
                    <FamilyName>Groves</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Kernis</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1991</Year>
                  <ArticleTitle Language="En">Survival in patients with primary pulmonary hypertension. Results from a national prospective registry</ArticleTitle>
                  <JournalTitle>Ann Intern Med</JournalTitle>
                  <VolumeID>115</VolumeID>
                  <FirstPage>343</FirstPage>
                  <LastPage>349</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.7326/0003-4819-115-5-343</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>1863023</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ZC</Initials>
                    <FamilyName>Jing</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XQ</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZY</Initials>
                    <FamilyName>Han</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Wu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KW</Initials>
                    <FamilyName>Deng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZW</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XS</Initials>
                    <FamilyName>Cheng</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Xu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Chest</JournalTitle>
                  <VolumeID>132</VolumeID>
                  <FirstPage>373</FirstPage>
                  <LastPage>379</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1378/chest.06-2913</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17400671</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007;132:373–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Thenappan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SJ</Initials>
                    <FamilyName>Shah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Gomberg-Maitland</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">A USA-based registry for pulmonary arterial hypertension: 1982–2006</ArticleTitle>
                  <JournalTitle>Eur Respir J</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>1103</FirstPage>
                  <LastPage>1110</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD2sjhs1aisg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1183/09031936.00042107</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17804449</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur Respir J. 2007;30:1103–10.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Gomberg-Maitland</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Dufton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Oudiz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RL</Initials>
                    <FamilyName>Benza</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective</ArticleTitle>
                  <JournalTitle>J Am Coll Cardiol</JournalTitle>
                  <VolumeID>57</VolumeID>
                  <FirstPage>1053</FirstPage>
                  <LastPage>1061</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXkslWntLk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jacc.2010.11.020</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21349396</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol. 2011;57:1053–61.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GC</Initials>
                    <FamilyName>Kane</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Maradit-Kremers</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Slusser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CG</Initials>
                    <FamilyName>Scott</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RP</Initials>
                    <FamilyName>Frantz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MD</Initials>
                    <FamilyName>McGoon</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Chest</JournalTitle>
                  <VolumeID>139</VolumeID>
                  <FirstPage>1285</FirstPage>
                  <LastPage>1293</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1378/chest.10-1293</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21071530</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011;139:1285–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SP</Initials>
                    <FamilyName>Gaine</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LJ</Initials>
                    <FamilyName>Rubin</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Primary pulmonary hypertension</ArticleTitle>
                  <JournalTitle>Lancet</JournalTitle>
                  <VolumeID>352</VolumeID>
                  <FirstPage>719</FirstPage>
                  <LastPage>725</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK1czpslahsw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0140-6736(98)02111-4</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>9729004</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719–25.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Malenfant</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AS</Initials>
                    <FamilyName>Neyron</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Paulin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Potus</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Meloche</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Provencher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bonnet</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Signal transduction in the development of pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Pulm Circ</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>278</FirstPage>
                  <LastPage>293</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.4103/2045-8932.114752</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24015329</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3757823</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Malenfant S, Neyron AS, Paulin R, Potus F, Meloche J, Provencher S, Bonnet S. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013;3:278–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PM</Initials>
                    <FamilyName>Hassoun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Mouthon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Barbera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Eddahibi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SC</Initials>
                    <FamilyName>Flores</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Grimminger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PL</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ML</Initials>
                    <FamilyName>Maitland</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ED</Initials>
                    <FamilyName>Michelakis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NW</Initials>
                    <FamilyName>Morrell</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Inflammation, growth factors, and pulmonary vascular remodeling</ArticleTitle>
                  <JournalTitle>J Am Coll Cardiol</JournalTitle>
                  <VolumeID>54</VolumeID>
                  <FirstPage>S10</FirstPage>
                  <LastPage>19</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXkvVOks7o%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jacc.2009.04.006</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19555853</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10–19.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Crosswhite</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Molecular mechanisms of pulmonary arterial remodeling</ArticleTitle>
                  <JournalTitle>Mol Med</JournalTitle>
                  <VolumeID>20</VolumeID>
                  <FirstPage>191</FirstPage>
                  <LastPage>201</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.2119/molmed.2013.00165</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24676136</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4002851</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Crosswhite P, Sun Z. Molecular mechanisms of pulmonary arterial remodeling. Mol Med. 2014;20:191–201.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Galie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Manes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Branzi</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">The endothelin system in pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Cardiovasc Res</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>227</FirstPage>
                  <LastPage>237</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXltFSlsw%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.cardiores.2003.11.026</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>14736539</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227–37.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Bouallegue</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GB</Initials>
                    <FamilyName>Daou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Srivastava</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Endothelin-1-induced signaling pathways in vascular smooth muscle cells</ArticleTitle>
                  <JournalTitle>Curr Vasc Pharmacol</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>45</FirstPage>
                  <LastPage>52</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXitlamsbo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2174/157016107779317161</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17266612</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol. 2007;5:45–52.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AH</Initials>
                    <FamilyName>Chester</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Yacoub</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">The role of endothelin-1 in pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Glob Cardiol Sci Pract</JournalTitle>
                  <VolumeID>2014</VolumeID>
                  <FirstPage>62</FirstPage>
                  <LastPage>78</LastPage>
                  <Occurrence Type="PID">
                    <Handle>25405182</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4220438</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.5339/gcsp.2014.29</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014:62–78.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Bressollette</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Dupuis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bonan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Doucet</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Cernacek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Tardif</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension</ArticleTitle>
                  <JournalTitle>Chest</JournalTitle>
                  <VolumeID>120</VolumeID>
                  <FirstPage>809</FirstPage>
                  <LastPage>815</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3Mrgs1OgtQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1378/chest.120.3.809</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11555514</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bressollette E, Dupuis J, Bonan R, Doucet S, Cernacek P, Tardif JC. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest. 2001;120:809–15.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Budd</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Holmes</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Targeting TGFbeta superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders</ArticleTitle>
                  <JournalTitle>Pharmacol Ther</JournalTitle>
                  <VolumeID>135</VolumeID>
                  <FirstPage>279</FirstPage>
                  <LastPage>291</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XpvVOntr0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.pharmthera.2012.06.001</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22722064</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Budd DC, Holmes AM. Targeting TGFbeta superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012;135:279–91.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Lambers</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Roth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Zhong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Campregher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Binder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Burian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Petkov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LH</Initials>
                    <FamilyName>Block</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">The interaction of endothelin-1 and TGF-beta1 mediates vascular cell remodeling</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>e73399</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhsVWht7%2FL</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0073399</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24015303</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3756002</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lambers C, Roth M, Zhong J, Campregher C, Binder P, Burian B, Petkov V, Block LH. The interaction of endothelin-1 and TGF-beta1 mediates vascular cell remodeling. PLoS One. 2013;8:e73399.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Singh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Ma</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Berlin</FamilyName>
                  </BibAuthorName>
                  <Year>2016</Year>
                  <ArticleTitle Language="En">Pathophysiology of pulmonary hypertension in chronic parenchymal lung disease</ArticleTitle>
                  <JournalTitle>Am J Med</JournalTitle>
                  <VolumeID>129</VolumeID>
                  <FirstPage>366</FirstPage>
                  <LastPage>371</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC28XnvV2lsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.amjmed.2015.11.026</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26706386</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Singh I, Ma KC, Berlin DA. Pathophysiology of pulmonary hypertension in chronic parenchymal lung disease. Am J Med. 2016;129:366–71.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Seeger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Adir</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JA</Initials>
                    <FamilyName>Barbera</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Champion</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JG</Initials>
                    <FamilyName>Coghlan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Cottin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Marco</FamilyName>
                    <Particle>De</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Galie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Ghio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Gibbs</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Pulmonary hypertension in chronic lung diseases</ArticleTitle>
                  <JournalTitle>J Am Coll Cardiol</JournalTitle>
                  <VolumeID>62</VolumeID>
                  <FirstPage>D109</FirstPage>
                  <LastPage>116</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jacc.2013.10.036</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24355635</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62:D109–116.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Weijun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Zhenshun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Qiuyue</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Ting</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Min</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Transforming growth factor-beta1 induces epithelial-mesenchymal transition in A549 cells by up-regulating expression of calpain</ArticleTitle>
                  <JournalTitle>Zhonghua Jie He He Hu Xi Za Zhi</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>202</FirstPage>
                  <LastPage>205</LastPage>
                  <Occurrence Type="PID">
                    <Handle>26269309</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Weijun T, Zhenshun C, Qiuyue T, Ting W, Min L, Li Z. Transforming growth factor-beta1 induces epithelial-mesenchymal transition in A549 cells by up-regulating expression of calpain. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38:202–5.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YS</Initials>
                    <FamilyName>Jang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KS</Initials>
                    <FamilyName>Eom</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YI</Initials>
                    <FamilyName>Hwang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HR</Initials>
                    <FamilyName>Kang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SH</Initials>
                    <FamilyName>Jang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CH</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YB</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MG</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IG</Initials>
                    <FamilyName>Hyun</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells</ArticleTitle>
                  <JournalTitle>J Korean Med Sci</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>898</FirstPage>
                  <LastPage>904</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXhsVWrtb%2FM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3346/jkms.2007.22.5.898</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17982242</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2693860</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, Kim CH, Park YB, Lee MG, Hyun IG, et al. Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J Korean Med Sci. 2007;22:898–904.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kasai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Mason</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Kamimura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT)</ArticleTitle>
                  <JournalTitle>Respir Res</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>56</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1465-9921-6-56</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15946381</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>1177991</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Ramos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Becerril</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Montano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Garcia-De-Alba</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Ramirez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Checa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Pardo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Selman</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway</ArticleTitle>
                  <JournalTitle>Am J Physiol Lung Cell Mol Physiol</JournalTitle>
                  <VolumeID>299</VolumeID>
                  <FirstPage>L222</FirstPage>
                  <LastPage>231</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhtVOhtLjP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1152/ajplung.00070.2010</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20495078</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ramos C, Becerril C, Montano M, Garcia-De-Alba C, Ramirez R, Checa M, Pardo A, Selman M. FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010;299:L222–231.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>YH</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PB</Initials>
                    <FamilyName>Ouyang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Tian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XJ</Initials>
                    <FamilyName>Guo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XC</Initials>
                    <FamilyName>Duan</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Rosiglitazone inhibits TGF-beta 1 induced activation of human Tenon fibroblasts via p38 signal pathway</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>e105796</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0105796</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25144187</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4140818</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Luo YH, Ouyang PB, Tian J, Guo XJ, Duan XC. Rosiglitazone inhibits TGF-beta 1 induced activation of human Tenon fibroblasts via p38 signal pathway. PLoS One. 2014;9:e105796.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Dagher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Hutton</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JE</Initials>
                    <FamilyName>Bourke</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells</ArticleTitle>
                  <JournalTitle>Respir Res</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>21</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1465-9921-11-21</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20178607</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2844370</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res. 2010;11:21.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Tontonoz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BM</Initials>
                    <FamilyName>Spiegelman</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Fat and beyond: the diverse biology of PPARgamma</ArticleTitle>
                  <JournalTitle>Annu Rev Biochem</JournalTitle>
                  <VolumeID>77</VolumeID>
                  <FirstPage>289</FirstPage>
                  <LastPage>312</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXos1ekur4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1146/annurev.biochem.77.061307.091829</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18518822</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289–312.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Hamblin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Fan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YE</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">PPARs and the cardiovascular system</ArticleTitle>
                  <JournalTitle>Antioxid Redox Signal</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>1415</FirstPage>
                  <LastPage>1452</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXkvVGnsLs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/ars.2008.2280</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19061437</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2737093</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009;11:1415–52.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Martin-Nizard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Furman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Delerive</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Kandoussi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Fruchart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Staels</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Duriez</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells</ArticleTitle>
                  <JournalTitle>J Cardiovasc Pharmacol</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>822</FirstPage>
                  <LastPage>831</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XovFOqs7c%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1097/00005344-200212000-00003</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12451315</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B, Duriez P. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol. 2002;40:822–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EK</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YM</Initials>
                    <FamilyName>Oh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YS</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats</ArticleTitle>
                  <JournalTitle>Respirology</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>659</FirstPage>
                  <LastPage>668</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1440-1843.2010.01756.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20546541</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kim EK, Lee JH, Oh YM, Lee YS, Lee SD. Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats. Respirology. 2010;15:659–68.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BY</Initials>
                    <FamilyName>Kang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Kleinhenz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TC</Initials>
                    <FamilyName>Murphy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Hart</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo</ArticleTitle>
                  <JournalTitle>Am J Physiol Lung Cell Mol Physiol</JournalTitle>
                  <VolumeID>301</VolumeID>
                  <FirstPage>L881</FirstPage>
                  <LastPage>891</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXhs12ntbvP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1152/ajplung.00195.2011</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21926265</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3233829</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kang BY, Kleinhenz JM, Murphy TC, Hart CM. The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2011;301:L881–891.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TD</Initials>
                    <FamilyName>Schmittgen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KJ</Initials>
                    <FamilyName>Livak</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Analyzing real-time PCR data by the comparative C(T) method</ArticleTitle>
                  <JournalTitle>Nat Protoc</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>1101</FirstPage>
                  <LastPage>1108</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXmvVemt7c%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nprot.2008.73</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18546601</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Talati</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>West</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TR</Initials>
                    <FamilyName>Blackwell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JE</Initials>
                    <FamilyName>Loyd</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Meyrick</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension</ArticleTitle>
                  <JournalTitle>Am J Physiol Lung Cell Mol Physiol</JournalTitle>
                  <VolumeID>299</VolumeID>
                  <FirstPage>L363</FirstPage>
                  <LastPage>373</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXht1Wnsr%2FF</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1152/ajplung.00295.2009</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20562228</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2951074</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Talati M, West J, Blackwell TR, Loyd JE, Meyrick B. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;299:L363–373.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>West</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension</ArticleTitle>
                  <JournalTitle>Adv Exp Med Biol</JournalTitle>
                  <VolumeID>661</VolumeID>
                  <FirstPage>265</FirstPage>
                  <LastPage>278</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhsFyjtrrO</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/978-1-60761-500-2_17</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20204736</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:265–78.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibUnstructured>Ferreira Rde C, Montenegro SM, Domingues AL, Bandeira AP, Silveira CA, Leite LA, et al. TGF beta and IL13 in schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups. BMC Infect Dis. 2014;14:282. doi: <ExternalRef><RefSource>10.1186/1471-2334-14-282</RefSource><RefTarget TargetType="DOI" Address="10.1186/1471-2334-14-282"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Kulasekaran</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Scavone</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Rogers</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Arenberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>VJ</Initials>
                    <FamilyName>Thannickal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Horowitz</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation</ArticleTitle>
                  <JournalTitle>Am J Respir Cell Mol Biol</JournalTitle>
                  <VolumeID>41</VolumeID>
                  <FirstPage>484</FirstPage>
                  <LastPage>493</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXht1Squ7fE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1165/rcmb.2008-0447OC</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19188658</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2746991</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41:484–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Jonitz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Fitzner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Jaster</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells</ArticleTitle>
                  <JournalTitle>World J Gastroenterol</JournalTitle>
                  <VolumeID>15</VolumeID>
                  <FirstPage>4143</FirstPage>
                  <LastPage>4149</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXhtFSju77K</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.3748/wjg.15.4143</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19725148</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2738810</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jonitz A, Fitzner B, Jaster R. Molecular determinants of the profibrogenic effects of endothelin-1 in pancreatic stellate cells. World J Gastroenterol. 2009;15:4143–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Castanares</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Redondo-Horcajo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Magan-Marchal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Dijke</FamilyName>
                    <Particle>ten</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Lamas</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Rodriguez-Pascual</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation</ArticleTitle>
                  <JournalTitle>J Cell Sci</JournalTitle>
                  <VolumeID>120</VolumeID>
                  <FirstPage>1256</FirstPage>
                  <LastPage>1266</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXltF2js7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1242/jcs.03419</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17376964</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Castanares C, Redondo-Horcajo M, Magan-Marchal N, ten Dijke P, Lamas S, Rodriguez-Pascual F. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J Cell Sci. 2007;120:1256–66.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XY</Initials>
                    <FamilyName>Tian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Rosiglitazone attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the Rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors</ArticleTitle>
                  <JournalTitle>PPAR Res</JournalTitle>
                  <VolumeID>2014</VolumeID>
                  <FirstPage>374075</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1155/2014/374075</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24701204</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3950948</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Liu Y, Tian XY, Huang Y, Wang N. Rosiglitazone attenuated endothelin-1-induced vasoconstriction of pulmonary arteries in the Rat model of pulmonary arterial hypertension via differential regulation of ET-1 receptors. PPAR Res. 2014;2014:374075.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GP</Initials>
                    <FamilyName>Star</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Giovinazzo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Langleben</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells</ArticleTitle>
                  <JournalTitle>Vascul Pharmacol</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>45</FirstPage>
                  <LastPage>50</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXhsV2nsrfM</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.vph.2008.09.001</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18849010</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul Pharmacol. 2009;50:45–50.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>XK</Initials>
                    <FamilyName>Tong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Hamel</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Transforming growth factor-1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase</ArticleTitle>
                  <JournalTitle>Mol Pharmacol</JournalTitle>
                  <VolumeID>72</VolumeID>
                  <FirstPage>1476</FirstPage>
                  <LastPage>1483</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/mol.107.039602</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tong XK, Hamel E. Transforming growth factor-1 impairs endothelin-1-mediated contraction of brain vessels by inducing mitogen-activated protein (MAP) kinase phosphatase-1 and inhibiting p38 MAP kinase. Mol Pharmacol. 2009;72:1476–83.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Varga</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ML</Initials>
                    <FamilyName>Whitfield</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Transforming growth factor-beta in systemic sclerosis (scleroderma)</ArticleTitle>
                  <JournalTitle>Front Biosci (Schol Ed)</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>226</FirstPage>
                  <LastPage>235</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.2741/s22</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed). 2009;1:226–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR41">
                <CitationNumber>41.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Tian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WT</Initials>
                    <FamilyName>Wong</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XY</Initials>
                    <FamilyName>Tian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor</ArticleTitle>
                  <JournalTitle>Hypertension</JournalTitle>
                  <VolumeID>56</VolumeID>
                  <FirstPage>129</FirstPage>
                  <LastPage>135</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXnsFGkur0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1161/HYPERTENSIONAHA.110.150375</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20516393</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tian J, Wong WT, Tian XY, Zhang P, Huang Y, Wang N. Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension. 2010;56:129–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR42">
                <CitationNumber>42.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Iglarz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Touyz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Amiri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MF</Initials>
                    <FamilyName>Lavoie</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>QN</Initials>
                    <FamilyName>Diep</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EL</Initials>
                    <FamilyName>Schiffrin</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension</ArticleTitle>
                  <JournalTitle>Arterioscler Thromb Vasc Biol</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>45</FirstPage>
                  <LastPage>51</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhvVI%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1161/01.ATV.0000047447.67827.CD</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12524223</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45–51.</BibUnstructured>
              </Citation>
              <Citation ID="CR43">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AC</Initials>
                    <FamilyName>Montezano</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Amiri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RC</Initials>
                    <FamilyName>Tostes</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Touyz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EL</Initials>
                    <FamilyName>Schiffrin</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Inhibitory effects of PPAR-gamma on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats</ArticleTitle>
                  <JournalTitle>J Am Soc Hypertens</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>150</FirstPage>
                  <LastPage>160</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jash.2007.01.005</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20409845</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Montezano AC, Amiri F, Tostes RC, Touyz RM, Schiffrin EL. Inhibitory effects of PPAR-gamma on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats. J Am Soc Hypertens. 2007;1:150–60.</BibUnstructured>
              </Citation>
              <Citation ID="CR44">
                <CitationNumber>44.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CF</Initials>
                    <FamilyName>Lin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KC</Initials>
                    <FamilyName>Young</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CH</Initials>
                    <FamilyName>Bai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BC</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CT</Initials>
                    <FamilyName>Ma</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YC</Initials>
                    <FamilyName>Chien</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CL</Initials>
                    <FamilyName>Chiang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>Liao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HW</Initials>
                    <FamilyName>Lai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CW</Initials>
                    <FamilyName>Tsao</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN</ArticleTitle>
                  <JournalTitle>Biomed Res Int</JournalTitle>
                  <VolumeID>2014</VolumeID>
                  <FirstPage>787924</FirstPage>
                  <Occurrence Type="PID">
                    <Handle>24757676</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3971553</Handle>
                  </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1155/2014/787924</Handle>
</Occurrence>
                </BibArticle>
                <BibUnstructured>Lin CF, Young KC, Bai CH, Yu BC, Ma CT, Chien YC, Chiang CL, Liao CS, Lai HW, Tsao CW. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int. 2014;2014:787924.</BibUnstructured>
              </Citation>
              <Citation ID="CR45">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Matsumoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Kobayashi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Kamata</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals</ArticleTitle>
                  <JournalTitle>J. Smooth Muscle Res</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <FirstPage>41</FirstPage>
                  <LastPage>55</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1540/jsmr.44.41</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18552452</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Matsumoto T, Kobayashi T, Kamata K. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J Smooth Muscle Res. 2008;44:41–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR46">
                <CitationNumber>46.</CitationNumber>
                <BibUnstructured>Bum-Yong K, Park KK, Green DE, Bijli KM, Searles CD, Sutliff RL, Michael H. Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature. Plos One. 2013;8:e79503.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
